Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cytopenia Clear all
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Early Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

NCT00361296
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
K562/GM-CSF cell vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 23, 2026, 8:19 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

NCT07603557
View directory record Official record
Conditions
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Interventions
BMS-986353, Fludarabine Phosphate, Cyclophosphamide
Biological · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

NCT03866577
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Biological: M254, Placebo, Intravenous immunoglobulin (IVIg)
Biological · Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Whittier, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

NCT01355289
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 4 Interventional

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis
Interventions
Argatroban
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
Up to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2007 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

NCT02273960
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 3 Interventional Results available

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

NCT04784455
View directory record Official record
Conditions
Thrombotic Microangiopathies
Interventions
nomacopan (rVA576)
Drug
Lead sponsor
AKARI Therapeutics
Industry
Eligibility
6 Months to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational

A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients

NCT07805408
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

The SOLID Platelet Study

NCT03712618
View directory record Official record
Conditions
Platelet Transfusion Refractoriness (PTR), Thrombocytopenia
Interventions
Platelet Transfusion - LONG Platelet Transfusion, Platelet Transfusion - SHORT Platelet Transfusion
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

NCT00493181
View directory record Official record
Conditions
Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
Interventions
Interleukin-11 (IL-11 or Neumega)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2012 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

NCT01164215
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea, Neutropenia
Interventions
fluorouracil, leucovorin, oxaliplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Asheville, North Carolina • Greensboro, North Carolina • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

NCT01193348
View directory record Official record
Conditions
Atypical Hemolytic-Uremic Syndrome
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Atlanta, Georgia • Hackensack, New Jersey • Corpus Christi, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

NCT03399461
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
Patient Interview guide, Caregiver interview guide, Sociodemographic questionnaire, Pediatric quality of life (PedsQL) questionnaire, Clinical questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 30 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Collegeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340
View directory record Official record
Conditions
Neutropenia, Breast Cancer
Interventions
SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
49
States / cities
Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279
View directory record Official record
Conditions
Myelofibrosis, Thrombocytopenia
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

EXTEND (Eltrombopag Extended Dosing Study)

NCT00351468
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag olamine (SB-497115-GR)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational Results available

Home Away From Home - Medical Outcomes

NCT02774850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Bacteremia
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 19 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

NCT07738822
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Interventions
Velinotamig specified dose on specified days.
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

NCT05345561
View directory record Official record
Conditions
Fetal and Neonatal Alloimmune Thrombocytopenia
Interventions
Clinical data collection
Other
Lead sponsor
Rallybio
Industry
Eligibility
18 Years and older · Female only
Enrollment
14,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
19
States / cities
Chandler, Arizona • Gardena, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

NCT00914927
View directory record Official record
Conditions
Thrombocytopenia Related to Chronic Liver Disease
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting No phase listed Observational

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183
View directory record Official record
Conditions
Atypical Hemolytic-Uremic Syndrome
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02872103
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
F-627, Placebo
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 74 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 23, 2026, 8:19 PM EDT